CIK 0001501796 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Aura Biosciences, Inc.
Sign in to watch- Ticker
- AURA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 320271970
- Phone
- (617)500-8864
- Business address
- 80 GUEST STREET, BOSTON, MA, 02135
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-11-02 | de los Pinos Elisabet See Remarks | Conversion | +4,552 | 131,412 | ||
| 2021-11-02 | de los Pinos Elisabet See Remarks | Conversion · Series A-1 Preferred Stock | −3,042 | 0 | ||
| 2021-11-02 | de los Pinos Elisabet See Remarks | Conversion · Series A-2 Preferred Stock | −1,510 | 0 | ||
| 2021-11-02 | Johnson David Michael Director | Conversion | +139,672 | 139,672 | ||
| 2021-11-02 | Johnson David Michael Director | Conversion · Series E Convertible Preferred Stock | −139,672 | 0 | ||
| 2021-10-28 | Johnson David Michael Director | Grant or award · Stock Option (Right to Buy) | +24,000 | 24,000 | ||
| 2021-10-28 | Rich Cadmus See Remarks | Grant or award | +26,250 | 26,250 | ||
| 2021-10-28 | Rich Cadmus See Remarks | Grant or award · Stock Option (Right to Buy) | +112,500 | 112,500 | ||
| 2021-10-28 | de los Pinos Elisabet See Remarks | Grant or award | +74,357 | 74,357 | ||
| 2021-10-28 | de los Pinos Elisabet See Remarks | Grant or award · Stock Option (Right to Buy) | +318,750 | 318,750 | ||
| 2021-10-28 | De Rosch Mark Chief Operating Officer | Grant or award | +17,500 | 17,500 | ||
| 2021-10-28 | De Rosch Mark Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2021-10-28 | Mattessich Antony C. Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2021-10-28 | Feder Julie B Chief Financial Officer | Grant or award | +26,250 | 26,250 | ||
| 2021-10-28 | Feder Julie B Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +112,500 | 112,500 | ||
| 2021-10-28 | PAREKH RAJESH B Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2021-10-28 | Primiano Christopher Brett Chief Business Officer | Grant or award | +8,750 | 8,750 | ||
| 2021-10-28 | Primiano Christopher Brett Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +37,500 | 37,500 | ||
| 2021-10-28 | Srivastava Sapna Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 |
Page 11 of 11 · 219 trades